Key result
Review underscores familial dysbetalipoproteinemia as an underdiagnosed, highly atherogenic lipid disorder.
Why the study?
Familial dysbetalipoproteinemia is an understudied and rarely diagnosed atherogenic disorder, and clinicians often lack a clear understanding of its clinical course and genetic basis.
Answers are grounded in this paper and cite their sources.
This review provides a comprehensive overview of familial dysbetalipoproteinemia to aid clinicians in timely diagnosis and appropriate lipid-lowering therapy.
Familial dysbetalipoproteinemia (FD) is a genetic, highly atherogenic disorder. The penetrance of FD depends on the patient’s lifestyle and concomitant diseases. Despite the fact that FD was described almost half a century ago, it is still insufficiently studied and is extremely rarely diagnosed. In actual clinical practice, physicians do not have clear understanding of clinical course and genetic basis of FD. The aim was to present the most complete, but at the same time a critical review with a modern view on FD. We analyzed Russian and foreign publications from following electronic databases: PubMed, eLIBRARY, Google Scholar. As a result, the phenotypic features and genetic variability of the disease were considered and the main issues of diagnosis and treatment of patients with FD were discussed. The data presented will help the clinician to timely suspect the FD, conduct a full range of investigations and prescribe evidence-based lipid-lowering therapy.
No takes yet. Share an insight, caveat, or question.
Блохина et al. (2021) conducted a review in Familial dysbetalipoproteinemia. Familial dysbetalipoproteinemia was evaluated. Familial dysbetalipoproteinemia is a highly atherogenic and underdiagnosed genetic disorder requiring timely clinical suspicion, comprehensive investigation, and evidence-based lipid-lowering therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: